Moving beyond feature lists: Unlocking growth through whole-pathway value
And an action plan for leaders
While product teams focus on marketing technical differentiation and feature lists, modern healthcare buyers evaluate risk mitigation, capacity expansion, and systemic cost reduction.
Health systems increasingly move towards value-based procurement and buyers do not purchase isolated technical capabilities and seek pathway efficiency, bed-day creation, and acute admission avoidance.
To achieve sustainable adoption and secure enterprise-wide contracts, growth leaders must fundamentally re-architect their go-to-market propositions. The solution lies in transitioning from point-solution selling to a whole-pathway value framework ,aligning product capabilities directly with health system financial, operational, and clinical realities and local commissioning structures.
The strategic failure of feature-based selling
Selling point solutions into complex healthcare ecosystems creates structural friction. When commercial messaging is rooted in product features rather than clinical pathways, it fails to answer the questions that matter to procurement boards:
Point-solution fatigue. For example: An acute care provider is overloaded with disconnected software tools and standalone devices that increase administrative burden rather than streamlining workflows.
Misalignment with financial realities. For example: Demos highlighting algorithmic accuracy or user interface design fail to address fundamental buyer questions regarding tariff alignment, bed-day reduction, or staff capacity creation.
The split-incentive dilemma or the wrong-pocket-problem: For example: Value generated in one department (e.g., outpatient monitoring) often accrues as financial savings in another (e.g., acute emergency admissions). Feature lists fail to address these cross-budget dynamics.
The whole-pathway value framework
To unlock adoption, commercial strategy must transition from product-centric messaging to a three-pillar whole-pathway value framework.
Pillar I: Aligning with commissioning realities and reimbursement structures
Growth requires mapping clinical utility directly to regional commissioning priorities and existing reimbursement mechanisms.
Tariff integration: Define explicitly whether the solution unlocks existing billing codes, leverages value-based incentives, or generates direct cost avoidance.
Budget attribution: Identify exactly which budget holder captures the savings, structuring commercial terms to align costs with realised financial benefits.
“If your remote-monitoring tool saves outpatient time, but the system's financial savings are realised by avoiding acute emergency costs, your business case must explicitly bridge those two siloed budgets.”
Pillar II: Quantifying capacity creation and admission avoidance
Procurement decisions in resource-constrained health systems are driven by capacity management, not just clinical efficacy alone. For example:
Bed-day reduction: Quantify the reduction in length of stay and delayed transfers of care.
Acute care decompression: Position solutions around shifting care from high-cost acute settings into community, primary, or home-care environments.
Workforce efficiency: Express ROI in terms of clinical hours saved and staff throughput rather than vague productivity gains.
“Do not simply claim your software "saves time." Demonstrate how liberating 40 nursing hours a week translates directly into reducing expensive agency staff or increasing elective surgical throughput.”
Pillar III: Building localised real-world evidence (RWE)
Clinical trials validate safety and efficacy, but commercial adoption requires real-world operational proof.
Pragmatic evidence generation: Establish pilot frameworks designed to measure operational and financial metrics alongside clinical outcomes.
Scalable business cases: Use early implementation data to build repeatable, localised business cases that address regional health system mandates.
“Treat your first pilot not just as a clinical trial, but as a financial sandbox. The goal is to generate the localised operational data required to defend your premium pricing against lower-cost competitors.”
Operationalising the shift: An action plan for leaders
To transition your organisation toward pathway-led growth, you must align three distinct commercial functions:
Commercial strategy (the message): Restructure your sales collateral. Replace product feature matrices with total-cost-of-care reduction models and pathway impact maps. Upskill your market access and sales teams in health economics so they can confidently engage CFOs and Medical Directors in financial terms.
Product strategy (the build): Align your development roadmap with procurement realities. Prioritise clinical workflow integration, seamless EHR data interoperability, and automated outcome reporting over marginal algorithmic enhancements that buyers won't pay for.
Market Access (the proof): Structure early-adopter pilot deployments as strategic co-development alliances. The goal of early deployments should be to co-create system-level evidence that proves operational ROI, thereby building a commercial moat around your value proposition.
One action for you, right now
Take a hard look at your current sales deck and commercial strategy: are you leading with product specs, or are you leading with whole-pathway clinical and economic value?
If you are ready to re-architect your go-to-market strategy for true enterprise adoption, let's connect to build your framework.
Buoyancy Health Strategy
Steady. Strategic. Scalable Healthcare Growth
© 2025 Buoyancy Health Strategy Ltd. All rights reserved.